2309/ 93, med senere ændringer, når det gælder de centralt godkendte produkter indeholdende celecoxib (Onsenal), parecoxib (Dynastat/ Rayzon) og valdecoxib (Bextra/ Valdyn), hvilket blev påbegyndt i november 2004.
Further to discussions at the CHMP October 2004 plenary meeting, the European Commission recommended that this public health issue on all aspects of cardiovascular safety including thrombotic events and cardio-renal events is the subject of Community referrals under Article 31 of Directive 2001/ 83/ EC, as amended regarding decentrally authorised products containing celecoxib, etoricoxib and lumiracoxib and subject to a review procedure under Article 18 of Council Regulation (EEC) No 2309/ 93, as amended regarding the centrally authorised products containing celecoxib (Onsenal), parecoxib (Dynastat/ Rayzon) and valdecoxib (Bextra/ Valdyn), which were started in November 2004.